Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease

European Journal of Internal Medicine

Volumn 22, Issue 5, 2011, Pages 518-521

  Caravita, Sergio ^a   Wu, Sheng Chin ^a   Secchi, Maria Beatrice ^a   Dadone, Viola ^a   Bencini, Chiara ^a   Pierini, Simona ^a  

^a PARKINSON INSTITUTE   (Italy)

Author keywords

6 Min Walk Distance; Intravenous cyclic Iloprost; NT proBNP; Pulmonary arterial hypertension; Raynaud phenomenon; Scleroderma

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ILOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DOPPLER ECHOCARDIOGRAPHY; DRUG INTERMITTENT THERAPY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; LUNG ARTERY PRESSURE; MALE; MIXED CONNECTIVE TISSUE DISEASE; MULTIPLE CYCLE TREATMENT; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; WALKING;

ADULT; AGED; CARDIOVASCULAR AGENTS; CONNECTIVE TISSUE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PULMONARY WEDGE PRESSURE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052963673     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.02.005     Document Type: Article

References (31)

1. F.M. Wigley Clinical practice: Raynaud's phenomenon N Engl J Med 347 2002 1001 1008
2. L.K. Hummers, and F.M. Wigley Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma Rheum Dis Clin North Am 29 2003 293 313 (Pubitemid 36765122)
3. F.M. Wigley, R.A. Wise, and J.R. Seibold Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study Ann Intern Med 120 1994 199 206
4. D. Launay, E. Diot, and E. Pasquier Bosentan for treatment of active digital ulcers in patients with systemic sclerosis Presse Méd 35 2006 587 592 (Pubitemid 43907154)
5. J.H. Korn, M. Mayes, and M. Matucci Cerinic Digital ulcers in systemic sclerosis:prevention by treatment with bosentan, an oral endothelin receptor antagonist Arthritis Rheum 50 2004 3985 3993 (Pubitemid 39643947)
6. C.L. Colglazier, P.G. Sutej, and K.S. O'Rourke Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil J Rheumatol 32 2005 2440 2442 (Pubitemid 41780663)
7. R. Fries, K. Shariat, H. von Wilmowsky, and M. Böhm Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy Circulation 112 2005 2980 2985 (Pubitemid 41612301)
8. K.A. Fagan, and D.B. Badesch Pulmonary arterial hypertension associated with connective tissue disease A.J. Peacock, L.J. Rubin, Pulmonary circulation 2004 Arnold Publishers London 181 190
9. M. McGoon, D. Gutterman, and V. Steen American College of Chest Physicians. Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126 2004 14S 34S (Pubitemid 38932340)
10. E. Hachulla, V. Gressin, and L. Guillevin Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study Arthritis Rheum 52 2005 3792 3800 (Pubitemid 41798217)
11. American Thoracic Society ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
12. V. Steen, and T.A. Medsger Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement Arthritis Rheum 48 2003 516 522 (Pubitemid 36278021)
13. S.C. Plastiras, S.P. Karadimitrakis, and C. Kampolis Determinants of pulmonary arterial hypertension in scleroderma Semin Arthritis Rheum 36 2007 392 396 (Pubitemid 46776817)
14. V.V. McLaughlin, K.W. Presberg, and R.L. Doyle American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126 2004 78S 92S (Pubitemid 38932344)
15. R. Condliffe, D.G. Kiely, and A.J. Peacock Connective tissue disease associated pulmonary arterial hypertension in the modern treatment era Am J Respir Crit Care Med 179 2009 151 157
16. C.F. Opitz, R. Wensel, and J. Winkler Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension Eur Heart J 26 2005 1895 1902 (Pubitemid 41253303)
17. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788 (Pubitemid 34925627)
18. V.V. McLaughlin, S.P. Gaine, R.J. Barst Treprostinil Study Group Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 2003 293 299 (Pubitemid 36135255)
19. V.F. Tapson, M. Gomberg-Maitland, and V.V. McLaughlin Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial Chest 129 2006 683 688
20. P. Airò, M. Rossi, and M. Scarsi Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group Clin Exp Rheumatol 25 2007 722 727 (Pubitemid 350284844)
21. P. Caramaschi, A. Volpe, and I. Tinazzi Does cyclically Iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results Rheumatol Int 27 2006 203 205 (Pubitemid 46088283)
22. I. Bartosik, J. Eskilsson, and A. Scheja Intermittent Iloprost infusion therapy of pulmonary hypertension in scleroderma - a pilot study Br J Rheumatol 35 1996 1187 1190
23. Task force on the diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-2278.
24. D. Chemla, V. Castelain, and M. Humbert New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure Chest 126 2006 1313 1317
25. F.M. Wigley, J.A. Lima, and M. Mayes The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study) Arthritis Rheum 52 2003 2125 2132 (Pubitemid 40994336)
26. N. Galie, A. Manes, and A. Branzi The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Eur Respir J 20 2002 1037 1049 (Pubitemid 35175146)
27. M.H. Williams, C.E. Handler, and R. Akram Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma associated pulmonary arterial hypertension Eur Heart J 12 2006 1485 1494 (Pubitemid 43998084)
28. Y. Allanore, D. Borderie, and J. Avouac High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis Arthritis Rheum 58 2008 284 291
29. T. Dimitroulas, G. Giannakoulas, and H. Karvounis N-Terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension Clin Rheumatol 27 2008 655 658
30. S. Hearth, E.L. Salerno, and N. Rothfield Brain natriuretic peptide levels correlate with six minute walk distance and World Health Oraganization Functional Classification in patients with connective tissue disease-associated pulmonary arterial hypertension Chest 128 2005 219(S)
31. N. Galiè, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, and J.A. Barbera Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Heart J 30 2009 2493 2537